Michael Ho, MD
Neurology · Santa Monica, CANPI 1013171834
Payments from drug & device makers
Across 495 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- UCB, Inc.$1K
- AbbVie$1K
- Neurocrine Biosciences, Inc.$1K
- AstraZeneca$692
- Amgen$483
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$731%
- Food & beverage$10,38898%
- Education$921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 76 | $1,627 |
| UCB, Inc. | 77 | $1,419 |
| AbbVie(2 entities) | 61 | $1,344 |
| Neurocrine Biosciences, Inc. | 60 | $1,181 |
| AstraZeneca | 28 | $692 |
| Amgen(2 entities) | 20 | $483 |
| Lilly USA, LLC | 21 | $441 |
| EMD Serono, Inc. | 19 | $334 |
| Biogen | 14 | $319 |
| Lundbeck LLC | 13 | $287 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $246 |
| Sunovion Pharmaceuticals Inc. | 10 | $233 |
| Sumitomo Pharma America, Inc. | 10 | $202 |
| SK Life Science, Inc. | 7 | $201 |
| Biohaven Pharmaceuticals, Inc. | 9 | $194 |
| Pfizer | 7 | $166 |
| Novartis | 8 | $160 |
| Abbott | 1 | $141 |
| Acadia Pharmaceuticals Inc | 5 | $110 |
| Acorda Therapeutics, Inc | 5 | $109 |
| Greenwich Biosciences, Inc. | 4 | $106 |
| Mallinckrodt Hospital Products Inc. | 3 | $90 |
| Eisai Inc. | 4 | $83 |
| Amneal Pharmaceuticals LLC | 4 | $67 |
| Neurelis, Inc. | 4 | $66 |
| Genentech USA, Inc. | 1 | $33 |
| Integra Lifesciences Corporation | 1 | $32 |
| Bausch Health US, LLC | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Aquestive Therapeutics, Inc. | 1 | $21 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$141
How this compares
$10,553 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AptiomEslicarbazepine Acetate | 52 | $144,876 |
| RebifInterferon Beta-1a/Albumin | 13 | $132,064 |
| XcopriCenobamate | 37 | $80,148 |
| UbrelvyUbrogepant | 29 | $54,551 |
| BriviactBrivaracetam | 29 | $53,568 |
| Nurtec OdtRimegepant Sulfate | 16 | $27,512 |
| KeppraLevetiracetam | 11 | $23,052 |
| Lacosamide | 84 | $10,749 |
| DepakoteDivalproex Sodium | 12 | $9,971 |
| Levetiracetam | 170 | $7,877 |
| NayzilamMidazolam | 11 | $6,493 |
| Carbamazepine ErCarbamazepine | 22 | $4,272 |
| Carbamazepine | 31 | $2,737 |
| Clobazam | 52 | $2,475 |
| Oxcarbazepine | 21 | $2,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sunovion Pharmaceuticals Inc.Aptiom | $233 | $144,87652 claims |
| EMD Serono, Inc.Rebif | $334 | $132,06413 claims |
| SK Life Science, Inc.Xcopri | $201 | $80,14837 claims |
| UCB, Inc.Briviact, Nayzilam | $1,419 | $60,06240 claims |
| AbbVieUbrelvy | $1,344 | $54,55129 claims |
| PfizerNurtec Odt | $166 | $27,51216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.
Other neurology in Santa Monica
- David KudrowSanta Monica$12.8M
- Naveed WagleSanta Monica$1.8M
- Santosh KesariSanta Monica$1.6M
- Timothy CloughesyLos Angeles$33.1M
- Jack FlorinFullerton$13M
- John Ravitsla Jolla$8.4M
- Perminder BhatiaFresno$8.3M
- Perry ShiehLos Angeles$8.2M
- Benjamin FrishbergCarlsbad$8.2M
- Bruce CreeSan Francisco$8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.